Concord Biotech Limited IPO Message Board (Page 42)

Concord 166/171

Roj GMP girane se accha hai sidha 0 krdo ...mat lagao yar koi bhi yeh ipo .. dam ni hai isme na iske promoters mai na LM mai na anchors mai... Kyuki GMP kisi bhi bhav par sambhal ni rhi inse. ! ESI company ka ipo undersubscribe hi jane do.

Sahi baat hai !!

🚨 Mainline IPO GMP 🚨

₹75 Yatharth Hospital IPO
₹42 SBFC Finance IPO
₹180 Concord Biotech IPO
₹55 Balaji Speciality Chem. IPO

Concord Biotech Ipo
Allotment chance higher then sbfc ipo

Concard chances of allotment is more here and retail and hni may earn handsome if they took some risk.... Sbfc allotment will be tough... Now pharma is in limelight better go for concard over sbfc if limited funds, esle apply both ff...

Bm surna ji kindly guide
Sbfc ya Concord kaunsa ipo lagao?

Ya dono laga do?

Any listing gain idea in both IPO?

Any one idea Concord Biotech IPO is risk free or not?

A little risk always stays there but in my opinion it should not list negative.
I am applying FF there.

Dear all, please let me know which bank provide facility of minor ASBA application.
Thanks.

I use ICICI since years

are you sure about icici & hdfc asba facility for minor applicants as on their webpage its clearly mentioned that its not for minors.....?

Please update the gmp so that we can apply on Monday

Capital Market Rating

Concord : 44
SBFC : 45
Utkarsh:45
Senco:45
Cyient:45
Yathartha:46

Off topic
If someones interested in Kaynes or EMS, should definitely read this quarter con-call transcript of KAYNES. Doing capex, foray into new segments(osat, its a big business as seen from their comments), smart meters,railway signals(90% share) etc.
PS-i hold both kaynes and syrma from ipo. NOT advising anyone to buy at this level. Shld grab when in correction.

And I sold kaynes hni lot on listing :⁠'⁠(

Im holding both Kaynes ans Syrma from ipo
Growth of ems expected to be around 40%
Let's ride trending sector
Also Kaynes bussines is so good
Heard that they are coming to semiconductor bussines too and recently
Kaynes announced in Q4FY23 earning call that they are starting production of laptops for a large semi-conductor company (IBM). This is interesting.
Will hold both for sometime and Ill add during all dips

@PKRAJ Absolute correct . If someone follow anyone then just try to add his own hidden wisdom alongwith the prevailing circumstances.....

There are 2-types of bHNI applicants

1. Having sufficient funds for just either one of SBFC or Concorde.
2. Funds are in abundance, shortage of demat accounts.

With the recent euphoria I'm expecting atleast 10% more bHNI applications in SBFC than Netweb (~50k bHNI applications).
So, expecting around 55000 applications (11.24x application wise).
Now, the ratio of category-1/category-2 applicants would actually determine subscription in Concorde.

If ratio 50-50
We may see 27500 bHNI applications (3.68x app wise) in Concorde.

If ratio is 25-75
We may see 41,250 bHNI applications (5.52x app wise) in Concorde.

Assuming that category-2 doesn't cross 75% of total.
The max application wise bHNI subscription would be 5.52x in Concorde.

Will try and post a similar analysis for sHNI category as well.

Listing gains in Concord are not sure. So, bHNI may be subdued to just about 2-3× application wise. Overall bHNI may be just in the range of 10-15× .

@Trueinfo , yes.
I mentioned the upper cap of bHNI subscription as 5.52x (app wise).
It should definitely be lower than that.
How much lower depends on the tomorrow's market sentiments.

PBT to CFOB4T conversion is 98%, 113% and 77% for the last 3 years
Borrowing has fallen consistently over last 3 years
EBITDA margin has fallen in 21-22 but since recovered a bit in 22-23 at 40.47%.
Comparison with Supriya Lifescience and Glenmark Lifescience on key financial parameters is provided below
Company       EV/ EBITDA       EBITDA Margin %      RoCE
Concord       22.54       40.47       24.7
Glenmark Lifescience      10.86       31       29.9
Supriya Lifescience       14.80       29       18.50

Fermentation capacity utilization was 47.36% in 22-23 and any improvement will deliver operating leverage. Formulation plant capacity utilization is dropping for last 3 years and is 9.92% for 22-23.
12% of total employees are in R&D indicating future focus of company
Top 10 customers contribute 44% of company’s sales in 22-23
As of March 31, 2023, company had 23 API products and had filed 128 Drug Master Files (“DMFs”) across several countries for its APIs apart from 77 approved products for formulations.
Exports as % of revenue have dropped from 59% in 20.21 to 49% in 22-23
Other income for 22-23 includes Rs 10 cr forex gain, subsidy income of Rs 8, recievables from BG of Rs 4.6 cr, gain on sale of investments of Rs 3 cr and insurance claim received of Rs 65 lacs. How much of these are sustainable is to be seen.
MF investments of Rs 137 cr and cash and bank balances of Rs 43 cr make this company a net debt free company. This along with healthy cash flow, sufficient head room for debt and low plant capacity utilisation imply company will be able to manage future capex for internal accruals and debt, if any. Hence very low chance of future equity dilution.
Company has invested Rs 5 cr in Trust Banking & PSU Fund, a fund sponsored by Utpal Sheth who is CEO of RaRe Enterprises (Rakesh Jhunjhunwala’s investment firm). RJ trusts have 24% stake in Concord

DEAR YBPK, Great in Detail Analysis of Every new main Board IPOS...Thanks keep it up....🙏

WHICH ARE THE INVESTORS WHO ARE TAKING EXIT IN THIS OFS?

GMP : 186-193

Yesterday spike was fabulous of 216 premium and back to pavallion again.

IPO applicants be like :-

ये टूटा [ दिल 💔IPO में शेयर नहीं मिलता ] ले के कहा जायेंगे
जाते जाते क्या ख्याल नही आया
तेरे [ IPO ] बिना हम मर जायेंगे!

@Palka CONCORD chahiye..🤗

Abhi aur dum lagao 195 gmp ho gai hai teji ko break lag gai hai isko bhi retail me 7 se 8 times bharna hai

*IPO Alert*
Balaji Speciality Chemical
BRLM - HDFC and JM
Anchor 17th aug
Issue open 18-22 aug
Issue size aprox - 425cr
Tentative price 170/180

GMP : 202

Est Subscription At This Premium

bhni : 20-25 x
sHni : 18-22 x
Retail : 6-7 x

BHNI MINIMUM 30 X

Ayega ke nai abhi itna? 🤔

I think Anil Singhvi has changed the game here.
There are lot of retail people who blindly follow his advice when it comes to IPO's.
Let's see if this one really does well or turns out to be another LIC.

If one wants allotment then apply here and if one wants safety then apply in SBFC.

@PKRAJ Absolute correct . If someone follow anyone then just try to add his own hidden wisdom alongwith the prevailing circumstances.....

Risk is there but figures are good it can be like Mankind Pharma or GLS time will tell.